LONDON, June 13, 2014 /PRNewswire/ --
The US markets on Thursday, June 12, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the session 0.71% lower at 1,930.11. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 688.58, down 0.56%, whereas the index has advanced 1.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), MiMedx Group Inc. (NASDAQ: MDXG) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). Free technical research on HEB, ICPT, MDXG and RPTP can be downloaded upon signing up at:
On Thursday, shares in Hemispherx Biopharma Inc. fell 1.74% to close the day at the intra-day low of $0.33. The stock recorded a trading volume of 0.86 million shares, below its three months average volume of 1.46 million shares. The company shares oscillated between $0.33 and $0.35 during the session. Over the last three trading sessions and over the past one month, Hemispherx Biopharma Inc.'s shares have gained 1.27% and 1.24%, respectively. Further, the stock has gained an upside of 26.08% since the start of this year. The stock is trading above its 200-day moving average of $0.31, while the 200-day moving average is below Hemispherx Biopharma Inc.'s 50-day moving average of $0.34. Additionally, the stock has a Relative Strength Index (RSI) of 52.27. Sign up today to read free research on HEB at:
On Thursday, shares in Intercept Pharmaceuticals Inc. recorded a trading volume of 0.47 million shares, lower than its three months average volume of 0.61 million shares. The stock ended the day at $278.64, which was 2.73% below its previous day's closing of $286.45, and registered an intraday range of $271.67 and $294.95. Although Intercept Pharmaceuticals Inc.'s stock has lost 2.72% in the previous three trading sessions, it has surged 11.43% in the last one month and 308.08% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $262.73 and $193.80, respectively. Furthermore, shares of Intercept Pharmaceuticals Inc. have an RSI of 59.79. Sign up today to read free research on ICPT at:
MiMedx Group Inc.'s stock finished the Thursday's session 0.66% lower at $6.05. A total of 0.32 million shares were traded, which was below its three months average volume of 0.61 million shares. The stock vacillated between $5.97 and $6.17 during the session. Over the last one month, MiMedx Group Inc.'s shares have gained 6.70%. However, the stock has lost 4.87% in the previous three trading sessions and 30.78% since the beginning of 2014. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $6.19 is greater than its 50-day moving average of $5.68. MiMedx Group Inc.'s stock has an RSI of 60.03. Sign up today to read free research on MDXG at:
On Thursday, shares in Raptor Pharmaceutical Corp. fluctuated between $10.55 and $11.34 before ending the session 4.73% higher at $11.30. The stock reported a trading volume of 1.00 million shares, close to its three months average volume of 0.98 million shares. Raptor Pharmaceutical Corp.'s shares have rallied 16.49% in the previous three trading sessions and 38.65% in the last one month, while the stock has lost 13.21% on YTD basis. The stock is trading above its 50-day moving average. Raptor Pharmaceutical Corp.'s 200-day moving average of $12.70 is above its 50-day moving average of $8.48. Moreover, shares of the company have an RSI of 72.50. Sign up today to read free research on RPTP at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.